SCHEMBL4470715

SCHEMBL4470715

O=C(Nc1ccc(CO)cc1)c1cc2cc(OCc3ccccc3)ccc2[nH]1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.66
ALDH1A1 P00352 1/20 0.66
CYP1A2 P05177 1/20 0.66
CYP2C9 P11712 1/20 0.66
HPGD P15428 1/20 0.66
SRD5A2 P31213 1/20 0.66
HSD17B10 Q99714 1/20 0.66
NHERF1 O14745 2/20 0.62
PYGL P06737 2/20 0.62
PDGFRB P09619 1/20 0.62
PDGFRA P16234 1/20 0.62
HDAC1 Q13547 1/20 0.57
HDAC2 Q92769 1/20 0.57
FLT3 P36888 1/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 2/20 0.52
POLB P06746 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13864630 0.88 KDM4E (0.61) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4484324 0.88 KDM4E (0.64) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4460774 0.88 KDM4E (0.64) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4460803 0.86 KDM4E (0.59) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4465153 0.86 KDM4E (0.61) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL13867216 0.86 KDM4E (0.56) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4461598 0.85 ALDH1A1 (0.58) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL13864726 0.85 KDM4E (0.58) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL14512076 0.85 KDM4E (0.58) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4466439 0.85 SMN1; SMN2 (0.58) KDM4EALDH1A1CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531668-B2 2-arylcarboxamide-nitrogenous heterocycle compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-05-12 US disclosed
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MSD K.K. (JP) 2007-12-27 US disclosed
EP-1798221-A1 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MCHR2, MCHR1, NPY2R KDM4E 2454/4885ALDH1A1 1060/4885CYP1A2 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.